摘要
【目的】探讨瑞舒伐他汀联合叶酸对高血压患者血清同型半胱氨酸（Hcy）、胱抑素C（CysC）、高敏C反应蛋白（hs—CRP）水平的影响。【方法】选择180例原发性高血压患者，按随机数字表法分为对照组（A组）、瑞舒伐他汀钙组（C组）及瑞舒伐他汀钙联合叶酸片组（C组），每组各60例。A组给予降压药物治疗，对伴有冠心病患者配合口服阿司匹林、硫酸氢氯吡格雷、硝酸酯类药物。B组在对照组用药基础上口服瑞舒伐他汀钙10mg，每晚1次。C组在B组基础上口服叶酸片5mg，3次／日，共治疗24周。分别于治疗前，治疗后第4周、第12周及第24周后测定晨起空腹静脉血血清Hcy、CysC、hs—CRP水平，比较三组治疗前、治疗后上述检测指标的变化。【结果】治疗前三组患者血清Hcy、CysC、hs—CRP水平对比无明显差异（P〉0．05）；治疗第12周时B组、C组上述指标较治疗前下降，差异具有统计学意义（P〈0．05）；治疗第24周时B组、C组上述指标较治疗第12周时进一步下降，并且C组下降幅度较B组更加明显，上述差异均有显著统计学意义（P〈0．05），而A组上述指标较治疗前稍下降，差异无统计学意义（P〉0．05）。【结论】瑞舒伐他汀钙具有降低高血压患者Hcy、CysC、hs—CRP水平作用，并且联合使用叶酸片时效果更明显，可作为临床辅助治疗、预防高血压相关靶器官损害。
[Objective]To investigate the effects of rosuvastatin and folic acid on level of serum homocysteine,cystatin and high sensitivity Creactive protein in hypertensive patients. [Methods] According to the table of random number, a total of 180 patients with primary hypertension treated in our hospital were divided to control group（group A）, rosuvastatin group（group B）, and rosuvastatin combined with folic acid group（group C）, 60 patients in each group respectively. Group A was treated antihypertensive therapy, those with coronary heart disease were treated with oral aspirin, clopidogrel and nitrates. On the basis of the group A, rosuvastatin was added to group B, 10mg PO PN. On the basis of the group B, folicacid was added to group C, 5mg PO Tid, for 24 weeks. Before treatment, at 4th week,12th week and 24th week after treatment, the fasting vessel vein blood in the morning was taken to measure the level of serum homocysteine ,cystatin C and high sensitivity Creactive protein respectively, the changes of the above indexes of the three groups before and after treatment were compared. [Results] There was no significant difference among the level of homocysteine, Cystatin C and high sensitivity C reactive protein from the three groups compared with those before treatment （ P〈0.05）, At twelfth week after treatment, the index of group B and group C decreased compared with those before treatment, the difference was statistically significant （ P〈0.05）; At 24th week after treatment, the above parameters of group B and group C dropped further compared with those of 12th week , and group C decreased more obviously than group B,the above differences were statistically significant （ P〈0.05）. The indexes in the group A were slightly lower than those before treatment, the difference was not statistically significant （ P〉0.05）.[Conclusion] Rosuvastatin can reduce the level of serum homocysteine, Cy-statin C and high sensitive Creactive protein in patients with hypertension, the effect is more obvious when it is combined with folic acid, and it can be used as a clinical adjuvant therapy to prevent hypertension-related target organ damage.
出处
《医学临床研究》
CAS
2016年第3期539-542,共4页
Journal of Clinical Research
